DPP4 and type 2 diabetes mellitus: They analyzed medical records of 798 patients with T2D to test if CDKAL1 genotype can influence therapeutic response to the following drug classes: biguanides, sulfonylureas, DPP-IV inhibitors, thiazolidinediones, glinides, and GLP-1RA.